Significance of measuring the severity of emphysema, in combination with spirometry, on the risk evaluation of patients undergoing major lung resection for cancer†

肺气肿严重程度测量联合肺功能测定对接受肺癌根治性肺切除术患者风险评估的意义†

阅读:1

Abstract

OBJECTIVES: Predicted postoperative forced expiratory volume in 1 s (ppoFEV1) and predicted postoperative diffusing capacity of the lungs for carbon monoxide (ppoDLco) are the two most significant parameters for predicting the risk of cardiopulmonary complications after major lung resection for lung cancer. Although the severity of pulmonary emphysema on computed tomography may be an important risk factor for postoperative complications, the clinical significance of measuring the severity of pulmonary emphysema, in combination with ppoFEV1 and ppoDLco, has never been evaluated. METHODS: We measured the severity of pulmonary emphysema, representing the percentage of low-attenuation area (< -950 Hounsfield units), in the whole lung field, in addition to ppoFEV1 and ppoDLco, in 451 patients who underwent major lung resection for primary lung cancer. We also measured the volume of the upper and lower lobes of emphysematous and non-emphysematous lungs. RESULTS: Postoperative cardiopulmonary complications developed in 60 patients (13.3%). According to a receiver operating characteristic curve analysis for the diagnostic potential of postoperative complications, the area under the curve was highest for the severity of emphysema, followed by ppoDLco and ppoFEV1. According to a stepwise multivariable logistic regression analysis, the severity of emphysema and ppoDLco was identified as independent risk factors for postoperative complications. Neither the heterogeneous distribution of emphysema nor that of non-emphysema was associated with the occurrence of complications in patients with upper lobe disease or in patients with lower lobe disease. CONCLUSIONS: The severity of emphysema on computed tomography is a relevant risk factor for cardiopulmonary complications after major lung resection. CLINICAL REGISTRATION NUMBER: The study was approved by our institutional review board of No. 240077.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。